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Abstract 
The regulation of blood glucose levels in humans, in response to insulin, is 
essential to survival. This response is mediated through the insulin responsive 
glucose transporter GLUT4.  In response to insulin stimulation GLUT4 is 
trafficked from intracellular insulin sensitive stores (GSVs GLUT4 storage 
vesicles) to the plasma membrane of fat and muscle cells allowing uptake of 
glucose into these cells and lowering of plasma glucose levels.  Previous work 
from our lab has identified that ubiquitination and subsequent deubiquitination 
of GLUT4 is required for entry and stability in GSVs. This balance of 
ubiquitination and deubiquitination in mammalian cells is carried out by E3 
ligases and deubiqutinating enzymes (DUBs).  It appears that E3 ligases allow for 
targeted entry of GLUT4 into insulin sensitive GSVs and that the DUB USP25 is 
required for GLUT4 to stably maintained in these GSVs.  Using a model 
developed in our lab my thesis looked at key steps of ubiquitination and 
deubiquitination to try and identify the E3 ligases and deubiquinases essential 
for entry and stability of GLUT4 into GLUT4 storage vesicles. 
Previous work in our lab identified that knockdown of the ubiquitin specific 
protease USP25 resulted in a reduction in GLUT4 levels in 3T3-L1 adipocytes.  In 
my thesis I looked at using an inducible retro viral system to identify if the 
catalytic activity of USP25 was required to maintain GLUT4 expression levels.  
This method had limited success as I was unable to produce a virus that would 
always express under induction. 
Previous work in our lab had also identified that GLUT4 was ubiquitinated in 
yeast and in 3T3-L1 adipocytes.  βTrCP had previously been identified as a 
possible E3 ligase that interacts with GLUT4 and so I used this as a candidate 
ligase.  To identify if βTrCP played a role in mediating insulin responsive glucose 
uptake I utilised siRNA knockdown of βTrCP in 3T3-L1 adipocytes alongside 
glucose uptake assays.  Although knockdown of βTrCP showed no effect on 
GLUT4 levels in 3T3-L1 adipocytes it did show a decrease in insulin responsive 
glucose uptake. 
These data did not provide any further information on the relationship between 
GLUT4 and USP25.  These data do however indicate that βTrCP does interact in 
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some way with insulin responsive glucose uptake in 3T3-L1 adipocytes but it is 
still unclear if this is due to any interaction with GLUT4. 
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Abbreviations  
~ Approximately 
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ARF ADP ribosylation factor 
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g gram 
xg multiple of gravitational force 
GAE γ adaptin ear 
GAT GGA and TOM1 
GFP Aequorea victoria green fluorescent protein 
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GLUT glucose transporter 
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GSV GLUT4 storage vesicle 
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Ig immunoglobulin isotype 
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k kilo (prefix) 
KCl potassium chloride 
K2HPO4 dipotassium hydrogen orthophosphate 
KH2PO4 potassium dihydrogen orthophosphate 
l litre 
LSB Laemmli’s sample buffer 
μ micro (prefix) 
m milli (prefix) 
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M molar 
MgSO4 magnesium sulphate 
min minute 
n nano (prefix) 
N-terminal Amino-terminal 
NaCl sodium chloride 
Na2HPO4 disodium hydrogen orthophosphate 
NaH2PO4 sodium dihydrogen orthophosphate 
NaOH sodium hydroxide 
NCS newborn calf serum 
NEM N-ethyl maleimide 
OD600 optical density at 600 nm 
PAGE polyacrylamide gel elecrophoresis 
PBS phosphate buffered saline 
PBS-T 0.1 % Tween-20 in phosphate buffered saline 
PCR polymerase chain reaction 
RNA ribonucleic acid 
RS retention sequence 
SDM site directed mutagenesis 
SDS sodium dodecyl sulphate 
siRNA short interfering RNA 
TAE tris-acetic acid-EDTA 
TE tris-EDTA 
TfR transferrin receptor 
TGN trans-Golgi network 
Ub ubiquitin 
v/v units per unit volume 
w/v units weight per unit volume 
YT yeast extract, tryptone, NaCl
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1 Introduction 
1.1 Diabetes 
Diabetes mellitus is a disease characterised by persistent hyperglycemia 
(Zimmet et al. 2001).  Normal blood glucose levels lie in the range of between 4 
and 7mM rising as high as 10mM after a carbohydrate rich meal (Zimmet et al. 
2001).  Glucose adsorbed in the intestine enters the blood stream and is 
detected at the β-cells of the pancreas (Zimmet et al. 2001).  This increase in 
blood glucose levels causes secretion of insulin from pancreatic  β-cells, which 
acts on adipose and muscle tissue to increase uptake of glucose from the blood 
and inhibits glucose production in the liver (Sesti 2006). This system is shown in 
figure 1.1.  
 
1.1 A diagrammatic representation of glucose homeostasis in the human body. 
Increases in blood glucose levels stimulate insulin release and subsequent lowering of blood 
glucose levels (orange arrows). Decreases in blood glucose levels stimulate glucagon release and 
raises blood glucose levels blue arrows.  Red spots represent the human blood stream.  
 
The persistent hyperglycemia characteristic of diabetes is due to no insulin 
production found in type-1 diabetes, or insulin resistance typical of type-2 
diabetes.  Type-1 diabetes or insulin dependent diabetes is a result of 
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autoimmune destruction of β-cell islets, leading to failure of insulin secretion or 
production (Saltiel & Kahn 2001).  Type-1 diabetes can be treated with insulin 
injections used to control blood glucose levels.  Type-2 diabetes is characterised 
by an underlying resistance to insulin.  In insulin-resistance insulin fails to lower 
plasma glucose levels due to a loss of responsiveness of fat and/or muscle. 
Persistently high blood glucose levels can lead to renal failure, vascular and 
cardiac disease and blindness (Saltiel & Kahn 2001).  Thus it is important blood 
glucose levels can be maintained at normal levels. 
In recent decades there has been a massive increase in the numbers of people 
with diabetes with estimates that more than 220 million people worldwide suffer 
from diabetes (Zimmet et al. 2001).  Type-1 diabetes makes up less than 10% of 
the population living with diabetes, with type-2 diabetes being the most 
prevalent.  The increasing number of individuals needing treatment for type-2 
diabetes is putting a strain on health services due to increased prescription of 
insulin sensitising drugs.  With secondary symptoms leading to type-2 individuals 
requiring time off from the workplace this also makes it a large financial 
problem.  With epidemic levels of type-2 diabetes worldwide it has been an 
important area of research for the last decade and with estimates of increasing 
numbers of sufferers of type-2 diabetes, it will remain to be an important area 
of study for the foreseeable future. 
1.2 GLUT4 
GLUT4 belongs to a family of  facilitative sugar transporters that are predicted 
to contain 12 membrane spanning domains with both their N and C terminus 
located intracellularly (Reviewed (Bryant et al. 2002; Watson et al. 2004).  
Based on their sequences and structural similarities these transporters have 
been separated into 3 subclasses of sugar transporters with different substrate 
specificity and tissue distribution. GLUT 1-4 are class I glucose transporters and 
their predicated topology is shown in figure 1.2 (Bryant et al. 2002).   
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1.2 Schematic representation of the topology of the class I GLUT family transport proteins. 
 
Within the class I glucose transporters, the different tissue distributions, various 
Km values and cellular localisation allow for regulation of glucose transport into 
different tissues under different physiological conditions.  GLUT 1 is expressed 
ubiquitously at the plasma membrane and is highly expressed in the brain and in 
erythrocytes (Reviewed (Watson et al. 2004)).  This distribution along with a Km 
below physiological glucose concentrations highlights GLUT1 as providing a 
constant level of glucose transport to maintain basal cellular function within all 
tissues.   GLUT4 is highly expressed in skeletal muscle and adipose tissue; under 
basal conditions GLUT4 is located in intracellular stores.  GLUT4 becomes rapidly 
localised to the plasma membrane of skeletal muscle during exercise and to the 
plasma membrane of skeletal muscle and adipose tissue upon insulin stimulation 
(Bryant et al. 2002; Watson et al. 2004).  This allows lowering of blood glucose 
levels after a meal and increased glucose transport to meet the additional 
energy needs of active muscle  (Bryant et al. 2002).  Translocation from 
intracellular stores to the plasma membrane allows for this regulation of glucose 
transport into fat and muscle cells. Even with 30 years of research since GLUT 4 
was identified as the insulin sensitive glucose transporter we do not fully 
understand all of the trafficking events involved in GLUT4 translocation to the 
plasma membrane.  For example how is GLUT4 targeted to the insulin sensitive 
compartment and what signals GLUT4 to translocate to the cell membrane in 
response to insulin?  [Bryant et al., 2002]. 
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1.3 GLUT4 storage vesicles 
GLUT4 storage vesicles are a population of subcellular compartments.  The main 
identifying feature of GSVs characterised in adipocytes is the lack of a 
transmembrane protein cellugyrin (Jedrychowski et al. 2010; Kupriyanova et al. 
2002). Previous work showed that GLUT4 and cellugyrin co-localised 
(Kupriyanova & Kandror 2000) but this population did not translocate to the cell 
surface in response to insulin.  Many of the other proteins present in GSVs have 
also been identified, the vesicle associated membrane protein 2 (VAMP2)(Cain et 
al. 1992; Martin et al. 1996), insulin responsive aminopeptidase (IRAP)(Ross et 
al. 1997a), low density liposome receptor related protein1(Jedrychowski et al. 
2010) and sortilin(Li et al. 2009). 
Sortilin is a 110kDa glycoprotein that has been identified as essential for the 
formation of GSVs (Lin et al. 1997; Morris et al. 1998).  Sortilin expression and 
formation of GSVs has been shown to occur 2 days post differentiation in 3T3-L1 
adipocytes (Shi & Kandror 2005).  shRNA knockdown of sortilin results in reduced 
formation of GSVs in an in vitro budding assay.  Further investigation also 
identified a reduction in insulin stimulated glucose transport (Shi & Kandror 
2005).  Myc tagged GLUT4 expressed on its own in 3t3-L1 fibroblasts resulted in 
rapid degradation of the protein.  Co-expression with sortilin stabilised the 
7myc-GLUT4 and allowed formation of GSVs in non differentiated 3t3-L1 cells 
shown by an increase in insulin responsive glucose uptake (Shi & Kandror 2005).  
Yeast two-hybrid and cross linking analysis has identified an interaction between 
the luminal domain of sortilin with those of both IRAP and GLUT 4 (Shi & Kandror 
2007). Formation of the insulin sensitive compartment is dependent upon these 
luminal interactions.  Expression of a truncated sortilin mutant resulted in only 
partial reconstitution of the insulin responsive compartment in undifferentitated 
3T3-L1 adipocytes(Shi et al. 2008; Shi & Kandror 2005). 
As noted above LRP1 has been identified as a cargo component of GSVs 
(Jedrychowski et al. 2010), and has been shown to also play a role in GSV 
formation and stability.  Cross linking analysis in rat epididymal adipocytes 
identified that LRP1 interacts with sortilin, IRAP and GLUT4.  Furthermore shRNA 
knockdown of LRP1 results in reduced levels of all three proteins (Jedrychowski 
et al. 2010). 
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1.4 GGA proteins 
One important stage in GLUT4 trafficking is sorting into GSVs. The GGA family of 
proteins have been implicated in this process. The GGA (golgi localised, gamma 
adaptin ear containing, Arf binding) proteins were identified as a family of 
clathrin adapter proteins.  There are two GGAs in yeast (gga1/2) and three in 
humans (GGA1,2 and 3).  The GGA proteins are comprised of 4 domains; a VHS 
(Vps 27, Hrs, STAM) domain which binds dileucine sorting motifs, a GAT (GGA 
and TOM1) domain capable of binding Arf-GTP and ubiquitin, the hinge region 
that binds clathrin and the GAE (gamma adaptin ear like domain that interacts 
with accessory proteins(Pelham 2004; Bonifacino 2004).  
 
 
1.3 Schematic showing domain structure of a typical GGA protein.  Adapted from (Pelham 
2004)  
 
GGA proteins have been shown to be involved in delivery of cargo proteins from 
the TGN into the endosomal system through the GGA interaction with ubiquitin 
moieties(Scott et al. 2004).   The GAT domain of GGA3 has been shown to bind 
to ubiquitin(Puertollano & Bonifacino 2004; Scott et al. 2004).  Scott et al 2004 
identified that GGAs were essential for sorting Gap1p directly from the TGN to 
endosomes in yeast.  Further experiments in yeast revealed that ggaΔ cells 
grown on a poor nitrogen source and switched to a higher nitrogen containing  
growth medium did not sort the Gap1p transporter for degradation(Scott et al. 
2004).  This sorting defect was also maintained when ubiquitin binding portions 
of the GAT domain are deleted, even though Gap1p is correctly ubiquintinated it 
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is not sorted to endosomes(Scott et al. 2004).  (Kawasaki et al. 2005) also 
identified that mutation of E250 and D258 of the GAT domain reduces in vitro 
binding of ubiquitin to the GAT domain of GGA3. 
In mammalian cells GGA3 has been identified as playing a role in sorting the EGF 
receptor(Puertollano & Bonifacino 2004).  siRNA depletion of GGA3 causes the 
EGF receptor and the cation independent manose-6 phosphate receptor to 
accumulate from the TGN and late endosomes to large early endosomes. 
This evidence highlights the interaction between GGAs and ubiquitin as a sorting 
signal for membrane proteins. 
1.5 Gap1p in Saccharomyces cerevisiae 
The yeast general amino acid permease Gap1p is a twelve transmembrane 
channel protein that is regulated in response to the nitrogen source on which the 
yeast are grown (Roberg et al. 1997).  When grown on poor nitrogen sources 
where amino acid uptake is essential Gap1p is trafficked to the plasma 
membrane.  However when grown on rich nitrogen sources such as glutamate 
Gap1p if trafficked to the endosomal system where it is eventually degraded at 
the vacuole (Roberg et al. 1997). 
Work investigating these alternate fates of Gap1p has identified that different 
ubiquitin modifications on Gap1p direct these different trafficking events.  
Monoubiqutination of Gap1p has been shown to result in internalisation of Gap1p 
from the plasma membrane (Risinger & Kaiser 2008). When Gap1p is 
polyubiquitinated this has been shown to result in trafficking directly to the 
vacuole (Risinger & Kaiser 2008).  This clearly indicates that membrane protein 
trafficking can be altered by external stimuli and the ubiquitin state of that 
protein. 
1.6 GLUT4 is ubiquitinated and deubiquitinated 
In the absence of insulin, GLUT4 is retained intracellularly, continually cycling 
through the trans-Golgi network (TGN), endosomal system and GLUT4 storage 
vesicles GSVs (Bryant et al. 2002). GSVs are defined as the compartment from 
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where GLUT4 is recruited to the plasma membrane in response to insulin. 
Previous work in looking at the trafficking of GLUT4 showed that in S. cerevisiae 
it was trafficked in a similar manner to that of Gap1p as detailed in section 1.5. 
Work carried out on 3T3-L1 adipocytes shows the GLUT4 transporter is 
ubiquitinated, furthermore trafficking of GLUT4 through the endosomal system 
to GSVs appears to be ubiquitin dependent as a mutant form of GLUT4 with all 7 
cytosolically exposed lysines fails to traffic to the cell surface in repsonse to 
insulin in 3T3-L1 adipocytes (Lamb et al. 2010). Restoration of ubiquitination to 
the 7K/R version of GLUT restores insulin responsiveness, however introduction 
of a constitutively ubiquitinated form of GLUT4 does not show an insulin 
responsive phenotype indicating that ubiquitination alone does not confer insulin 
sensitivity.  This is also supported by data that shows only approximately 0.1% of 
GLUT4 is ubiquitinated at steady state (Lamb et al. 2010). 
As previously noted to prevent ubiquitinated proteins from being degraded there 
is a requirement for a deubiquitinating enzyme to remove ubiquitin molecules. 
There are no DUBs known to be associated with GSVs however there does appear 
to be an association through a binding partner of the GSV cargo protein IRAP. 
IRAP has been found to traffic in a similar manner to GLUT4 in adipocytes (Ross 
et al., 1997). Work using siRNA depletion of IRAP showed a reduction in insulin 
stimulated GLUT4 translocation (Yeh et al. 2007). An interacting partner of IRAP 
is the poly-ADP ribose polymerase (PARP) Tankyrase(Sbodio et al. 2002). An 
interacting partner of Tankyrase is the ubiquitin specific protease USP25, siRNA 
mediated knockdown of USP25 carried out in our lab has revealed that USP25 
depletion results in a reduction of GLUT4 levels in 3T3-L1 adipocytes and a 
reduction in glucose uptake in response to insulin. These data suggest that 
USP25 may play a role in maintaining GLUT4 stability in GSVs by removing 
ubiquitin from GLUT4 molecules contained in GSVs and preventing their 
degradation.  
1.7 Ubiquitination 
As previously noted GGA proteins interact with ubiquitinated proteins and could 
therefore be involved in GLUT4 sorting.  Post translational modification of 
proteins occurs after their production and can include phosphorylation, 
lipidation and conjugation to other proteins.  Modification like this can act to 
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alter a proteins activity, localisation within a cell in a manner similar to the way 
internal trafficking motifs can affect sorting of the protein. 
Ubiquitin is a 76 amino acid polypeptide that acts as a post translational 
modification and was originally identified as APF-1 (ATP-dependent proteolysis 
factor 1) a protein of 8.5kD required for proteolysis, which could reversibly 
conjugate to protein substrates (reviewed(Ciechanover 2013)). 
Ubiquitin is conjugated to other proteins by forming an isopeptide bond between 
a lysine residue on the target protein and a glycine residue on the ubiquitin 
(Hicke & Dunn 2003).  Ubiquitin can become bound at one or multiple sites on a 
target protein and can also conjugate with itself forming polyubiquitin chains.  
Depending on the type of modification that occurs, soluble proteins can be 
degraded by the proteosome and membrane proteins can be trafficked through 
the endosomal system leading towards lysosomal degradation(Ciechanover 
2013). 
Ubiquitin conjugation to target proteins requires the action of 3 different 
enzymes.  E1 (ubiquitin activating) enzymes activate and form thiolester bond 
with the ubiquitin molecule.  Ubiquitin is then passed to an E2 by 
transthiolation.  The E2(ubiquitin conjugating) enzyme along with the E3 
(ubiquitin ligase) transfer the ubiquitin molecule to a lysine side chain of the 
target protein.  E3 enzymes provide the target specificity for ubiquitination and 
are therefore the key regulator of ubiquitination (Hicke & Dunn 2003). 
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1.4 Ubiquitin  conjugation to target proteins. 
A)Activation of ubiquitin by E1 enzyme forming a high energy thioester bond. B) Ubiquitin is 
transferred to E2 conjugating enzyme by a transthiolation reaction.  C) Working together E2 and E3 
enzymes form a thiolester intermediate on the E3 ligase. D) Ubiquitin is transferred to target 
protein. 
One fate of ubiquitinated proteins was degradation through the proteosome.  
This is a large 26s multi-enzyme complex consisting of a central core 20S particle 
with two 19S particles capped on either side acting to recognise ubiquitinated 
substrates(Voges et al. 1999).  Only substrates modified with a polyubiquitin 
chain of at least 4 molecules linked through lysine 48 (K48) are degraded in this 
manner (Acconcia et al. 2009; Ciechanover 2013).  Ubiquitinated proteins are 
not only degraded and current evidence shows that many plasma membrane 
receptors and channels can be internalised due to ubiquitination(Urbé 2005).  
Furthermore the recycling and resensitization of the β2 adrenergic receptor 
(Berthouze et al. 2009) and regulated surface expression of MHC II (major 
histochemically complex class II molecules) requires ubiquitination(Shin et al. 
2006).   
1.8 E3 ligases 
As it has already been noted ubiquitin can direct trafficking of membrane 
proteins to degradative pathways. In the same way removal of ubiquitin by DUBs 
(deubiquitinationg enzymes) can alter the trafficking of ubiquitinated proteins.  
There are approximately 79 DUBs present in the human genome and they are 
responsible for the cleavage of ubiquitin molecules from proteins and therefore 
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oppose the activity of E3 ligases (Komander et al. 2009). The DUBs have been 
sorted into five families; the ubiquitin C-terminal hydrolases (UCHs), ubiquitin-
specific proteases (USPs), ovarian tumor proteases (OTUs), Josephins and 
JAB1/MPN/MOV34 metalloenzymes (JAMMs and MPN+)(Reyes-Turcu et al. 2009).  
JAMM/MPN+ are zinc metalloproteases whereas the UCH,USP,OTU and Josephins 
are all cysteine proteases(Reyes-Turcu et al. 2009).  
1.9 Hypothesis and aims 
My current hypothesis is that GLUT4 requires ubiquitination and subsequent 
deubiquitination to enter and be stably maintained in GSVs. Figure 1.5 shows a 
mechanism for how this might be achieved. In this thesis I present experiments 
directed towards testing various aspects of this model.  Namely I plan to 
investigate; 
 A candidate E3 ligase that could be responsible for ubiquitination of 
GLUT4 and subsequent trafficking by GGA proteins to GSVs. 
 I also intend to further test the evidence that USP25 catalytic activity is 
required for insulin responsive GLUT4 translocation. 
 
1.5 Model of GLUT4 trafficking to GSVs and subsequent deubiquitination 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Reagents, enzymes and media components. 
All chemicals were from Sigma-Aldrich (Poole, Dorset, UK), VWR (Poole, Dorset, 
UK) or Fisher Scientific (Leicester, UK.) DNA restriction endonucleases, T4 DNA 
ligase and Pfu® polymerase were from Promega (Southhampton, UK). Platinum 
Pfx® polymerase and dNTPs were from Invitrogen (Paisley,UK). Fast Start High 
Fidelity polymerase was from Roche diagnostics (Burgess Hill, West Sussex, UK). 
Broad range protein markers were from Biorad (Hertfordshire, UK). Bacterial 
media components were from Melford Laboratories Ltd (Suffolk, UK) and 
Formedium (Hunstanton, Norfolk, UK).  Mammalian cell culture media 
components were from Invitrogen (Paisley, UK). Mirus TransIT TKO® transfection 
reagent was from Cambridge Bioscience Ltd (Cambridge, UK). 
2.1.2 Bacterial strains 
The bacterial strains used in this study are listed in Table 2.3 . Plasmids were 
maintained in XL-1Blue(Strategene) or TOP10 (Invitrogen) E.Coli. Recombinant 
proteins were expressed in BL-21 (DE3) cells (Invitrogen).  
2.2 Mammalian cell culture techniques 
2.2.1 Cell culture of 3T3-L1 murine fibroblasts and adipocytes 
3T3-L1 fibroblasts were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% (v/v) newborn calf serum (NCS).  Fibroblasts were 
maintained as subconfluent cultures at 37°C in a 10% CO2 humidified incubator.  
The fibroblasts were grown to confluency and maintained for up to 3 days before 
induction of differentiation by addition of DMEM supplemented with 10% (v/v) 
foetal bovine serum (FBS), 0.25μM dexamethasone, 0.5mM 3-isobutyl-1-
methylxanthine and 1μg/ml insulin.  After 3 days, the differentiation mixture 
was replaced with DMEM containing 10% (v/v) FBS and 1μg/ml insulin.  
Adipocytes were re-fed with media containing 10% (v/v) FBS at 2 to 3 day 
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intervals and used for experiments between day 8 and day 12 post 
differentiation. 
2.2.2 RNA oligonucleotide synthesis 
RNA nucleotide synthesis in this study was carried out by Qiagen (Crawley, West 
Sussex) and Dharmacon (Lafayette, Colorado). 
2.2.3 Transfection of 3T3-L1 adipocytes with siRNA 
oligonculeotides. 
At day 6 and 7 post differentiation, 3T3-L1 adipocytes were incubated with 
siRNA oligonucleotides (details in table) complexed with TransIT-TKO® 
transfection reagent (Mirus, Madison, WI) using an adapted version of the 
manufacturer’s protocol. For a 6 well plate, 5μl TransIT-TKO® and 5.3µl of 
75mM stock siRNA solution was combined with 100µl serum-free DMEM per well.  
After 20 minutes, this mixture was added drop wise to individual wells of a 6 
well plate.  This process was scaled up for larger culture dishes.  The siRNA 
treated adipocytes were then used for experiments on day 8 post 
differentiation.  
2.2.4 Retroviral infection of 3T3-L1 fibroblasts 
Fibroblasts were seeded to give approximately 40% confluency.  The next day, 
2ml of viral supernatant (produced as in (2.2.6) was combined with 2ml DMEM + 
10% FBS, and 10µg/ml polybrene.  This mixture was used to replace the 
fibroblast growth medium, and the cells were left to grow for 12 hours at 37°C.  
Cell were subsequently maintained in DMEM + 10% FCS with 2.5µg/ml puromycin 
to select for cells containing retrovirus.  On confluency the cells were then 
differentiated as in (2.2.1) without drug selection, and then maintained in DMEM 
+ 10% FBS with 2.5µg/ml puromycin until required for experiments. 
2.2.5 Cell Culture of Plat-E cells 
Plat-E cells were cultured in DMEM supplemented with 10% (v/v) FBS, 1µg/ml 
puromycin and 10μg/ml blasticidine. Cells were maintained as subconfluent 
cultures at 37°C in a humidified 5% CO2 incubator.  
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2.2.6 Preparation of retrovirus using Plat-E cells 
Cells were seeded at a density of 5 x 106 cells per 10 cm plate in DMEM + 10% 
FBS. On the following day, the cells were transfected with the appropriate 
retroviral constructs using Lipofectamine™2000.  Following transfection, cell 
were maintained in DMEM + 10% FBS for 48 hours at 37°C, and subsequently 
switched to 32°C overnight to induce virus particle production.  The viral 
supernatant was then harvested from the plates and stored at -80°C until 
required. 
2.2.7  Use of crystal violet for counting viral plaques 
For use in counting viral plaques for determining viral titres 1% crystal violet 
solution was prepared w/v in 20% ethanol.  Virally infected cells were washed 
with 1ml of phosphate buffered saline and then incubated for at least 10 
minutes with 1% crystal violet.  The cells were then washed with 10% v/v ethanol 
and subsequent plaques identified and counted. 
2.3 DNA manipulation 
Standard DNA manipulation procedures were used throughout the study  
2.3.1 Plasmid DNA purification 
Promega Wizard® Plus SV miniprep kits were routinely used to isolate DNA from 
small bacterial cultures (<10ml).  For larger preparations (>50ml) Qiagen® 
Plasmid Maxi kits were used 
2.3.2 DNA oligonucleotide synthesis 
DNA oligonucleotides were synthesised by Yorkshire Biosciences td (Heslington, 
York, UK) or IDT (Leuven, Belgium) and diluted in sterile double distilled water 
to a final concentration of 50pmol/μl before use. 
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2.3.3 Polymerase Chain Reaction 
The high fidelity Platinum Pfx® polymerase (Invitrogen) was routinely used to 
PCR amplify desired DNA sequences. 
A typical PCR mixture consisted of: 
10mM dNTPs     5μl 
50mM MgSO4     3μl 
10x Pfx buffer    5μl 
Enhancer solution    5μl 
ddH2O      28µl 
Forward primer (50pmol/µl stock) 1µl 
Reverse primer (50pmol/µl stock) 1µl 
Plasmid DNA     1µl 
Pfx DNA polymerase   1μl 
And the conditions normally used were: 
1.95°C  1 minute 
2.94°C  90 seconds 
3.56°C  1 minute 
4.68°C  1minute/kb 
5.68°C  10 minutes 
6.4°C  Final hold 
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Steps 2 to 4 were repeated 30 times during the course of the PCR. 
For amplification of larger templates and GC rich sequence the FastStart High 
Fidelity PCR system (Roche) was used.  The mixture in this case consisted of: 
10mM dNTPs     1μl 
10x Reaction buffer    5μl 
DMSO      1-5μl (2-10%) 
Forward primer (50pmol/μl stock) 4μl 
Reverse primer (50pmol/μl stock) 4μl 
Template DNA    1µl (600ng) 
2.5 U Fast Start High Fidelity enzyme 0.5µl 
ddH2O      to 50μl 
For templates less than 3kb, a reaction profile essentially the same as that for 
Pfx was utilised. For longer template the following was used: 
94°C  2 minute 
94°C  30 seconds 
52°C  30 minute 
68°C  1minute/kb 
94°C  30 seconds 
52°C  30 seconds 
68°c  1 min/kb (+ additional 20 seconds per cycle number) 
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68°C  7 minutes 
4°C   Final hold 
Steps 2-4 were repeated ten times during the course of the reaction, followed by 
25 cycles of steps 5-7. 
Electrophoresis was used to resolve DNA fragments genereated by PCR through 
0.8% (w/v) agarose in tris-acetate (TAE) buffer (40mM Tris acetate, 1mM EDTA).  
DNA fragments were extracted from agarose gels using the QIAquick® gel 
extraction kit (Qiagen). 
2.3.4 Site Directed Mutagenesis  
Site directed mutagenesis (SDM) of DNA sequences was performed using Pfu® 
polymerase (Promega) according to the Stratgene QuikChange® method. 
Synthetic oligonucleotides, were used to exchange on amino acid residue for 
another with the mutagenic codon at the approximate centre of the 
oligonucleotide.  A typical recipe for an SDM reaction is shown below: 
Purified template plasmid  50ng 
Forward primer   125ng 
Reverse primer    125ng 
10x Pfu Buffer   5μl 
10mM dNTPs    1μl 
Pfu Polymerase   1μl 
ddH2O       to 50μl 
Typical reaction conditions were: 
95°C   1 minute 
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95°C   50 seconds 
60°C   50 seconds 
68°C   16 minutes 
68°C   7 minutes 
4°C   Final Hold 
Steps 2 to 4 were repeated 20 times during the course of the reaction. On 
completion of the reaction, the samples were treated with 1μl (10 units) DpnI 
for 1 hour at 37°C, to digest methylated template DNA.  5μl of the final mixture 
was transformed into competent XL-1 Blue E.Coli, and transformants selected 
for on solid 2xYT (1.6% tryptone, 1% yeast extract, 0.5% NaCl) + 2% agar 
supplemented with 100μg/ml ampicillin.  Several resultant colonies were picked, 
grown up in 10ml of 2xYT + 100μg/ml ampicilin and plasmid purified.  Mutations 
were verified by DNA sequencing (Sequencing Service, University of Dundee). 
2.4 Protein Methods 
2.4.1 Electrophoretic separation of proteins 
The separation of proteins by electrophoresis was carried out with discontinuous 
polyacrylamide gels (SDS-PAGE) following the basic method outlined by Laemmli 
(1970).  Proteins were separated in gels composed of a stacking layer (5% 
acrylamide in a stacking buffer (0.25 M Tris-HCl (pH 6.8), 0.4% (w/v) SDS) and a 
separating layer (normally 10% acrylamide in separating buffer; 0.75 M Tris-HCl 
(pH 8.8), 0.4% (w/v) SDS).  A 30% acrylamide-bisacrylamide mixture 37.5:1 ratio 
Severn Biotech Ltd, Worcestershire) was used to make the gels.  The tris-glycine 
electrophoresis buffer used contained 25 mM Tris-HCl, 250 mM glycine, 
0.1%(w/v) SDS).  Resolved proteins were visualised on gels by agitiating the gels 
in Coomassie Brilliant Blue solution (0.25g Coomassie Brilliant Blue R250 in 
methanol: H2O: glacial acetic acid (4.5:4.5:1 v/v/v)) for 30 minutes, followed by 
overnight agitation in destain solution (10% (v/v) methanol, 10% (v/v) glacial 
acetic acid) to give clearly visible bands. 
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2.4.2 Transfer of proteins to nitrocellulose membranes 
A Bio-Rad Trans Blot® SD cell was used to transfer proteins from polyacrylamide 
gels onto nitrocellulose membranes (Protran, 0.45 μm pore).  Gels and 
membranes were sandwiched between 6 pieces of Whatman 3M filter paper 
soaked in semi dry transfer buffer (50 mM Tris-HCl, 40 mM glycine, .037% (w/v) 
SDS, 10% methanol.  The assembly was subject to a constant 180mA current for 
between 30 minutes (one gel) to one hour (three gels). 
2.4.3 Immunoblot analysis 
After protein transfer, unfilled site on the nitrocellulose membrane were 
blocked using 5% (w/v) non-fat dried milk in PBST 90.1% (v/v) Tween-20 in PBS) 
or TBST (0.1% (v/v) Tween-20 in Tris-HCl buffered saline (TBS – 0.5 M NaCl, 10m 
Tris-HCl pH7.6) according to the conditions required for each primary antibody.  
The membranes were exposed to primary antibody for 2 hours at room 
temperature or at 4°C overnight with agitation.  Primary antibodies were diluted 
as described in table 2.1. 
The membrane was subsequently washed six times with PBST/TBST for five 
minutes each.  The membranes were exposed to secondary antibody for between 
1 and 2 hours at room temperature, with agitation.  A further six 5 minute 
washes in PBST/TBST were carried out and protein bands visualised using 
enhanced chemiluminescence (ECL) or LiCor. 
2.4.4 Antibodies 
Primary and secondary antibodies used in this study are detailed in table2.1.  
Polyclonal antisera against USP25 was generated by Eurogentec (Liege, Belgium) 
using an 87 day protocol.  Briefly, two New Zealnd white rabbits were 
immunised with 100μg recombinant USP25 at days 0, 14, 28 and 56 of the 
protocol. Serum was collected from the rabbits before the first immunisation 
(pre immune), and on days 38, 66 and 87 subsequently. The sera were stored at 
-80°C until use. 
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2.4.5 IgG Antibody purification 
Sera collected from the final bleed on day 87 was combined 1:1 with phosphate 
buffered saline (PBS; 140 mM NaCl, 3 mM KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4) 
plus protease inhibitor tablet (Roche) (containing leupeptin, α2 macroglobulin, 
pefabloc SC, pepstatin, PMSF, chymostatin, E-64, bestatin, trypsin inhibitor).  
The subsequent mixture was incubated with 1ml of a 50% protein A-sepharose 
beads slurry with rotation for 1 hour. The beads were washed three times with 
cold PBS plus protease inhibitor cocktail (Roche).  Elution from the beads was 
achieved by addition of 6x500μl elution buffer (50mM glutamine, pH2.5).  The 6 
fractions were then neutralised by addition of 1M Tris, pH10 and dialised in PBS 
overnight. 
2.4.6 Quantification of Immunoblots 
Immunoblots were scanned using Phototshop® (Adobe) or transferred from 
Oddysey (LiCor) and immunoreactive bands measured using Image J software 
(National institutes of Health, USA).  The integrated density of each band was 
measured and a background reading for an equally sized area of the image 
subtracted to give a numeric value for the band intensity. 
2.4.7 GST fusion protein preparation 
For productions of USP25-GST, 10 ml of 2YT + 100μg/ml ampicillin was 
inoculated with E. coli BL-21 (DE-3) cells harbouring a plasmid encoding the 
appropriate GST fusion protein and incubated at 37 °C overnight with shaking. 
The 10ml culture was inoculated into 400 ml Terrific Broth (1.2 % (w/v) 
tryptone, 2.4 % (w/v) yeast extract, 0.4 % (w/v) glycerol, 0.05 M K2HPO4, 0.016 
M KH2PO4) and grown until OD600 = 0.6. Protein expression was induced with 
1mM IPTG and the cells were incubated for a further 4 hours at 37 °C with 
shaking. The cells were harvested by centrifugation and resuspended in 19.5 ml 
phosphate buffered saline (PBS; 140 mM NaCl, 3 mM KCl, 1.5 mM KH2PO4, 8 mM 
Na2HPO4). The cells were treated with lysozyme (1 mg/ml) on ice for 30 minutes 
and subsequently sonicated for five 30 second bursts with 30 second iced pauses. 
The lysate was spun at 17640 xg at 4 °C to remove insoluble components. The 
lysate was incubated with 1ml of a 50 % glutathione-Sepharose bead slurry with 
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rotation for 1 hour. The beads were washed three times with cold PBS to remove 
non-specifically bound proteins, and stored at 4 °C in PBS supplemented with 
EDTA free protease inhibitor cocktail (Roche) (containing leupeptin, α2 
macroglobulin, pefabloc SC, pepstatin, PMSF, chymostatin, E-64, bestatin, 
trypsin inhibitor) at a bead:buffer ratio of 1:1.  
2.5 [
3
H]2-Deoxyglucose uptake assays 
For these experiments cells were grown in 12 well plates.  After differentiation 
cells were serum starved for two hours.  Each twelve well plate was incubated 
at 37 C and washed four times with Krebs Ringer Phosphate (KRP; 128 mM NaCl, 
4.7 mM KCl, 5 mM NaH2PO4, 1.25 mM MgSO4, 1.25 mM CaCl2, pH7.4).  The wells 
of each plate were treated as follows for 30 minutes at 37 C: 
  3 wells 475 μl KRP (Basal) 
  3 wells 475 μl KRP + 1 mM insulin (Insulin) 
   3 wells 475 μl KRP + cytochalasin B (Basal CytoB) 
  3 wells 475 μl KRP + 1 mM insulin + cytochalasin B (Insulin CytoB) 
After the 30 minute incubation, 25 μl of [3H] deoxyglucose solution in KRP was 
added to the wells such that the final deoxyglucose concentration was 50 µM 
with 0.25 μCi per well.  After 5 minutes the contents of the wells was removed 
and the plates washed three times by immersion in ice cold PBS.  Cells were air 
dried for 1 hour at room temperature and solubilised in 1 ml 1 % Triton X-100 for 
2 hours.  Solubilised cells were transferred into scintiallation vials containing 5 
ml scintillation fluid, and radioactivity associated with the cells measured using 
liquid scintillation spectrophotometry.  
2.6 Indirect immunofluorescence  
3T3-L1 fibroblasts were grown on sterilised coverslips before differentiation.  
Cells were starved of serum using serum-free DMEM for two hours prior to 
starting the procedure, and treated with or without insulin for 15 minutes prior 
to fixing.  For surface epitope staining, cells were washed twice with PBS and 
fixed with 200 μl 3 % paraformaldehyde (PFA) for 30 minutes, washed twice with 
PBS then washed twice with 20 mM glycine (GLY) in PBS to quench free aldehyde 
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groups.  The coverslips were then incubated with 200 μl blocking solution (2% 
BSA/20 mM glycine in PBS (BSA/GLY)) for 20 minutes.  To incubate the cells with 
the primary antibody, the coverslips were placed cell side down onto a 40 μl 
drop of primary antibody preparation (dissolved in BSA-GLY) on parafilm for 45 
minutes, then washed four times with BSA/GLY.  Secondary antibody in BSA/GLY 
was applied to the cells in a similar manner for 30 minutes and then washed as 
previously.  The cells were returned to a 24 well plate, washed twice with PBS 
and surface bound antibodies fixed using 3 % PFA for 30 minutes.  The coverslips 
were washed twice with PBS and the PFA quenched with GLY as previously.  The 
cells were blocked and permeablised using 200 μl 20 mM glycine, 2 % BSA and 
0.1% saponin in PBS (BSA/GLY/SAP) for twenty minutes.  The coverslips were 
incubated with primary antibody preparation in BSA/GLY/SAP for 45 minutes, 
washed in BSA/GLY/SAP, incubated with secondary antibody for 30 minutes and 
given four further BSA/GLY/SAP washes.  The coverslips were washed finally in 
PBS, dried and mounted onto slides using Immumount (Thermo).  The mounted 
coverslips were analysed using a 63 x oil immersion objective lens fitted to a 
Zeiss LSM Pascal Exciter confocal fluorescence microscope, and images overlaid 
using LSM sofstware (Zeiss).  
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Antigen Working 
dilution 
Description Reference/ 
Source 
FAS 1:200 
(IB) 
Mouse monoclonal antibody 
against residues 9-202 of 
human fatty acid synthase. 
BD biosciences. 
GAPDH 1:30,000 
(IB) 
Mouse monoclonal antibody 
(clone 6C5) against GAPDH. 
 
Ambion® 
GLUT4 1:1000 
(IB) 
Rabbit polyclonal antibody 
against C-terminal 14 amino 
acids of GLUT4. 
 
Synaptic 
Systems. 
HA 1:1000 
(IB) 
1:200 
(IF) 
Mouse monoclonal antibody 
(clone 16B12) against an 
epitope from the human 
influenza haemagglutinin 
protein (YPYDVPDYA). 
 
Covance 
Research 
products 
Myc 1:1000 
(IB) 
1:500 
(IF) 
Rabbit polyclonal antibody 
raised against the myc epitope 
(EQKLISEEDL) conjugated to 
KLH. 
 
Abcam 
TrCP 1:500 
(IB) 
Rabbit polyclonal antibody 
raised against  amino acids 93-
384 of Human TrCP 
Abcam 
 
USP25 1:4000 
(IB) 
Rabbit polyclonal antibody 
raised against GST-USP25 
 
(Bosch-Comas 
et al., 2006) 
2.1 Antibodies used in this study 
Name Target Sequence Description 
Scrambled GACGAACAAACCGCCACATAT Scrambled control 
siRNA 
siRNA25 CCTGCTGGTTTAGTGCAGTTA Targeted against 
USP25 sequence 
obtained from 
Christopher Lamb 
PhD thesis 
siRNA27 CCCAACGATCACTGCAAGAAA As above 
βTrCP GTGGAATTTGTAGAACACC Purchased from 
Dharmacon® 
2.2 siRNA oligonucleotides used in this study 
 
 
Chapter 2  32 
 
 
Name Genotype Source 
BL-21(DE3) F
- ompT hsdSB(rB
-, mB
-) gal dcm 
(DE3) 
Invitrogen 
TOP10 F
- mcrA (mrr-hsdRMS-mcrBC) 
80lacZM15 lacX74 recA1 ara139 
(ara-leu)7697 galU galK rpsl 
(StrR) endA1 nupG 
Invitrogen 
XL-1 BLUE recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F’ proAB 
lacIqZΔM15 Tn10(Tetr0] 
Stratagene 
Table 2.3 Bacterial strains used in this study
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Chapter 3 βTrCP as a candidate E3 ligase 
3  
3.6 Introduction 
Previous work carried out by our group has shown that GLUT4 is ubiquitinated in 
3T3-L1 adipocytes (Lamb et al. 2010) and that ubiquitination is required for 
translocation of GLUT4 to the plasma membrane in response to insulin 
stimulation.  Ubiquitination is carried out by E3 ubiquitin ligase enzymes that 
provide target specificity for ubiquitination and are therefore key regulators of 
ubiquitination(Ciechanover 2013).  Previous work by (Govers et al. 1999) looked 
at ubiquitin dependent internalisation of growth hormone receptor and 
identified a novel ubiquitin conjugating motif.  Designated as the ubiquitin 
dependent endocytosis (UbE) motif, it has been shown to interact with the F-box 
protein βTrCP (Beta-transducin repeat containing E3 ubiquitin ligase) that forms 
part of the Skp1, Cullin, F-box (SCF) E3 ligase complex.  Other proteins 
suggested to contain a similar motif included GLUT4 and it was decided to 
investigate βTrCP as a candidate ligase for GLUT4 ubiquitination.  
Two approaches were chosen to test whether βTrCP acts as the ubiquitin ligase 
responsible for conferring insulin sensitivity to trafficking of GLUT4.  The first 
approach involved utilising retro viral expression of HA tagged GLUT4 constructs 
expressing Wt GLUT4 and GLUT4 V253A (a mutation to the proposed UbE motif) 
and see if this affected the ability of GLUT4 to translocate to the plasma 
membrane in response to insulin stimulation.  The second approach utilised 
siRNA mediated knockdown of βTrCP directly to see if how this affected GLUT4. 
3.7 Production of HA-GLUT4 V253A 
Previous work by (Govers et al. 1999) identified the ubiquitin dependent 
endocytosis motif (UbE) and identified that GLUT4 may contain a similar motif.  
Utilising this information and with the help of Professor Gwyn Gould we 
identified a possible motif in GLUT4. Figure 3.1 shows the sequence of human 
and mouse GLUT4 aligned with the proposed UbE motif. Previous work by 
(Govers et al. 1999)also identified that mutation of phenylalanine 327 to alanine 
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in the UbE motif resulted in failure of growth hormone receptor to be 
internalised.  To identify if a similar mutation could affect the ubiquitination of 
GLUT4 I produced a GLUT4 construct with a similar mutation.  Our lab has 
previously used retro virally expressed HA-GLUT4 (pRM55) and I decided to use 
this as a template for producing a version of GLUT4 with its putative UbE motif 
mutated. 
 
3.1 The UbE motif 
Alignment of Human and Mouse GLUT4 alongside the UbE motif, valine 253 is aligned with 
phenylalanine from the UbE motif. 
Using pRM55 as the template and oligonucleotides designed to produce a valine 
to alanine mutation, HA-GLUT4 V253A (pISA2) was produced and confirmed by 
sequencing.   
3.8 Expression of HA-GLUT4 V253A 
With both the wild type GLUT4 and the UbE mutant now in retroviral expression 
vectors I was now able to compare translocation of these two constructs.  The 
constructs were transfected into Plat-E cells to generate recombinant retrovirus 
and the virus was incubated with 3T3-L1 fibroblasts.  The fibroblasts were grown 
on sterile coverslips where they were grown to confluency before subsequent 
differentiation.  The adipocytes were then treated with or without insulin, 
before being fixed and stained for confocal microscopy. To differentiate from 
surface and total GLUT4 the cell were stained for the HA epitope prior to 
permeablisation to detect HA-GLUT4 at the surface membrane and again after 
permeablisation to show the total HA-GLUT4. 
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3.2 GLUT4 V253A fails to translocate in response to insulin 
3T3-L1 fibroblasts were infected with retroviral constructs encoding HA-GLUT4 or HA-GLUT4 
V253A, grown to confluency under selection with 2.5ug/ml puromycin and differentiated into 
adipocytes. Between days 8-12 post differentiation infected cells were treated with 170nM insulin 
for 20 minutes (insulin) or not (basal).  Cells were fixed with 3% (v/v) paraformaldehyde and 
stained for surface (Purple) and total HA epitope (green).  Scale bar = 20um  
The above data suggest that the V253A mutant lacks the ability to translocate to 
the plasma membrane in response to insulin.  The lack of surface staining 
(purple) present in the insulin treated cells indicates a failure to translocate to 
the plasma membrane.  To better represent this data I carried out cell counts to 
look at the percentage of cells with each construct showing translocation to the 
plasma membrane.  Three random fields of view were selected and a minimum 
of 50 cells per field were counted, cells were counted as showing surface 
staining if a defined membrane could be identified with the secondary surface 
stain (purple channel).  As table 3.1 shows about 21% of cells expressing HA-GLUT4 
V253A showed translocation to the plasma membrane compared to approximately 
86% in cells expressing the wild type HA-GLUT4. 
Chapter 3  37 
 
Basal Insulin 
HA-GLUT4 0 86.18% (± 1.24%) 
HA-GLUT4 
V253A 
0 21.27%(±7.05%) 
 
Table 3.1 Percentage translocation of HA-GLUT4 and HA-GLUT4 V253A in response to 
insulin. 
A minimum of 50 cells from three fields of view were counted for presence or absence of cell 
surface HA staining.  The results in the table are the mean of three experiments, expressed as the 
percentage of counted cells showing cells surface fluorescence ± standard error of the mean. 
   
The immunofluorescence data in figure 3.2 suggests that both the wt HA-GLUT4  
and the HA-GLUT4 V253A are expressed at similar level, to check the above data 
are not the result of different levels of expression of the constructs, plates of 
cells were grown in parallel to those grown on the coverslips.  As with the 
coverslips infected 3T3-L1 adipocytes were grown to confluency before 
differentiation, lysates were produced and subsequently run on SDS-PAGE before 
analysis by western blotting.  Figure 3.3 clearly shows that overall expression of 
GLUT4 V253A is reduced compared with the wild type HA-GLUT4 construct.   
 
 
3.3 Viral expression of HA-GLUT4 V253A is lower compared to Wt HA-GLUT4. 
3T3-L1 adipocytes were lysed in 50mM sodium HEPES, pH7.4, 150mM NaCl, 5mM EDTA, 1mM 
NEM, 1% v/v TRITON-X100 and protease inhibitors before homogenisation with 10 strokes with a 
needle and syringe. The lysates from these were centrifuged at 14000xg for 15 minutes and the 
supernatant removed from the pellet.  Protein concentrations were estimated by micro BCA assay 
and 20ug were loaded on a 7.5% gel (v/v) and immunoblotted for the HA epitope and GAPDH. 
Error bars represent ± standard error of the mean n=3 
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Given that the expressions levels are greatly reduced it is impossible to identify 
if the reduced translocation is due to the V253A mutation or just down to lower 
levels of HA-GLUT4.  To address this I introduced the use of a crystal violet 
method for estimating viral titre. The use of crystal violet made viral plaques 
much more visible and prevented miscounting of plaques giving a better 
estimation of the viral titre.  With this new system in place I proceeded to 
repeat the previous set of experiments. 
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3.4 Wt HA-GLUT4 and HA-GLUT4 V253A translocate to the plasma membrane in response to 
insulin.  
3T3-L1 fibroblasts were infected with retroviral constructs encoding HA-GLUT4 or HA-GLUT4 
V253A, grown to confluency under selection with 2.5ug/ml puromycin and differentiated into 
adipocytes. Between days 8-12 post differentiation infected cells were treated with 170nM insulin 
for 20 minutes (insulin) or not (basal).  Cells were fixed with 3% (v/v) paraformaldehyde and 
stained for surface (Blue) and total HA epitope (green).  Scale bar = 20um  
The data in figure 3.4 clearly indicates that HA-GLUT4 V253A translocates in a 
similar fashion to its wild type counterpart.  This data is supported by the cell 
counts shown in table 3.2 as it shows over 80% translocation to the plasma 
membrane by both of the constructs. This would suggest that the lack of 
translocation observed in figure 3.2 was likely due to under expression of the 
V253A mutant.  Expression levels of each construct were again checked using 
cells infected with the same batch of virus. 
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Basal Insulin 
HA-GLUT4 0 82.25%(±6.48%) 
HA-GLUT4-
V253A 
0.42%(±0.42%) 84.44%(±3.46%) 
 
Table 3-2 Percentage translocation of Wt HA-GLUT4 and HA-GLUT4 V253A in response to 
insulin. 
A minimum of 50 cells from three fields of view were counted for presence or absence of cell 
surface HA staining.  The results in the table are the mean of three experiments, expressed as the 
percentage of counted cells showing cells surface fluorescence ± standard error of the mean. 
 
 
3.5 HA-GLUT4 V253A expression is increased compared to the wild type HA-GLUT4. 
3T3-L1 adipocytes were lysed in 50mM sodium HEPES, pH7.4, 150mM NaCl, 5mM EDTA, 1mM 
NEM, 1% v/v TRITON-X100 and protease inhibitors before homogenisation with 10 strokes with a 
needle and syringe. The lysates from these were centrifuged at 14000xg for 15 minutes and the 
supernatant removed from the pellet.  Protein concentrations were estimated by micro BCA assay 
and 20ug were loaded on a 7.5% gel (v/v) and immunoblotted for the HA epitope and GAPDH. 
Error bars represent ± standard error of the mean n=3. 
Controlling expression of the V253A mutant has been shown to be difficult as 
figure 3.5 clearly shows that even with equal amounts of virus HA-GLUT4 V253A 
is expressing much more than its’ wild type counterpart.  I attempted multiple 
times to achieve equal expression of these constructs with retroviral expression 
but was unable to produce two sets of virus that resulted in equal expression of 
the two constructs.  As such no solid conclusions can be made from these data 
about the effect mutating the UbE motif has on translocation of GLUT4 to the 
plasma membrane. 
3.9 siRNA mediated knockdown of βTrCP 
To further investigate whether βTrCP plays a role in GLUT4 ubiquitination and 
subsequent trafficking to the insulin responsive compartment I decided to look 
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at the effects of knockdown of βTrCP in 3T3-L1 adipocytes.  As the lab had 
previously used the Mirus TransIT TKO system to achiever siRNA-mediated 
knockdowns in 3T3-L1s and a βTrCP siRNA oligonucleotide was commercially 
available I decided to proceed using these tools to investigate if knockdown of 
βTrCP would reduce insulin responsive glucose uptake.  Based on our model 
GLUT4 requires ubiquitination to enter GSVs and therefore knockdown of the E3 
ligase responsible for ubiquitination of GLUT4 would result in a reduction of 
insulin responsive glucose transport.   
 
3.6 siRNA mediated knockdown of βTrCP had no effect on GLUT4 expression levels. 
3T3-L1 adipocytes were treated with the indicated concentrations of siRNA specific to βTrCP and 
lysates were subject to immunoblot analysis following separation on a 7.5% (v/v) SDS-PAGE gel.  
Expression levels of FAS, GLUT4 and βTrCP were analysed by image J software and analysed 
with an un-paired T-Test *=P< 0.05. Error bars represent ± standard error of the mean n=3. 
The data in figure 3.6 show expression levels of GLUT4, FAS and βTrCP all 
normalised against GAPDH and then expressed as a percentage of the scrambled 
control. The right hand panel shows knockdown of βTrCP ranging from 
approximately 40-60% reduction in expression compared to the scrambled 
control. The data also indicates a trend towards increased expression of GLUT4 
in these cells.  This increase in GLUT4 levels however is not shown to be 
statistically significant.  To indentify if knockdown of βTrCP was altering insulin 
responsive glucose uptake I carried out deoxyglucose uptake assays with the 
siRNA treated 3T3-L1 adipocytes. 
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3.7 βTrCP reduces insulin responsive glucose uptake in 3T3-L1 adipocytes. 
12-well plates of 3T3-L1 adipocytes were treated with the indicated concentrations of siRNA and 
assayed for uptake of [
3
H] deoxyglucose on day 8 post differentiation.  Results were analysed 
using an unpaired student’s T-test. *-p<0.05. Error bars represent ± standard error of the mean 
n≥3.  
Figure 3.7 shows the uptake of [3H] deoxyglucose in 3T3-L1 adipocytes, treated 
with either scrambled siRNA or siRNA targeting βTrCP, under basal (blue) or 
insulin stimulated (red) conditions.  These data indicate a significant reduction 
(approximately 40%) in deoxyglucose uptake in 3T3-L1 adipocytes treated with 
400nm siRNA targeting βTrCP.  A small reduction was also seen in cells treated 
with 200nm siRNA but was not shown to be significant.  Across all repeats there 
appeared to be a trend for an increase in the basal transport of deoxyglucose, 
this was however not shown to be significant.   
3.10 Discussion 
The aim of the experiments in this chapter was to test βTrCP as a candidate E3 
ligase for GLUT4 ubiquitination.  To test this, I first looked at the UbE motif 
proposed to be present in GLUT4 (Govers et al 1999).  Using site directed 
mutagenesis and an HA-GLUT4 retroviral construct already commonly used in our 
lab I was able to produce HA-GLUT4 V253A.  Using indirect fluorescence 
microscopy I tried to identify if this mutation was altering GLUT4 trafficking in 
response to insulin stimulation in 3T3-L1 adipocytes.  Initial experiments 
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appeared to show a reduction in surface staining in cells expressing HA-GLUT4 
V253A (figure 3.2).  This was shown to be due to reduced expression levels of 
the HA-GLUT4 V253A (figure 3.3). After discussion with other virus users in the 
lab I decided to implement use of crystal violet for counting viral plaques for 
estimating my viral titre, the rational being that human error was resulting in an 
un-even number of viral particles being used between my two constructs.  After 
using this method and several repeats it became clear that getting equal 
expression of both constructs was proving to be incredibly difficult and it was 
decided to look at other ways of testing βTrCP as a candidate E3 ligase. 
Having previously used siRNA knockdown of other proteins in 3T3-L1 adipocytes I 
decided to use this method to look more directly at βTrCP.  With commercially 
available siRNA oligonucleotides and the trasfection system already established 
in our lab I wanted to initially see if I could successfully lower expression of 
βTrCP in 3T3-L1 adipocytes.  Initial attempts to lower expression of βTrCP using 
recommended concentrations of siRNA proved to show no effect on expression 
levels so I decided to try some higher concentrations of siRNA to see if I could 
produce knockdown.  I eventually found that at concentrations of 200-400nm I 
was able to achieve significant knockdown (figure3.6).  As I did not observe any 
toxic effects of these levels of oligonucleotides in either the scrambled control 
or βTrCP treated cells I decided to continue with further experiments. 
I wanted to address three key points regarding the βTrCP knockdown; did it have 
an effect on GLUT4 expression levels, did it alter insulin responsive glucose 
uptake and did it affect GLUT4 ubiquitination and ultimately translocation GSVs. 
To address the first point I carried out immunoblot analysis of 3T3-L1 lysates 
that had been treated with βTrCP siRNA.  I blotted all the samples for GLUT4, 
fatty acid synthase (FAS, as a marker of differentiation) and GAPDH as a loading 
control.  After analysis with ImageJ software and an un-paired T-test there was 
shown to be no statistical difference in GLUT4 or FAS levels in the treated cells 
compared to the scrambled controls.  These data would suggest that knockdown 
of βTrCP is having no effect on 3T3-L1 differentiation or on GLUT4 expression 
levels.  Continuing with siRNA knockdown I decided to look at the effect on 
glucose uptake (figure 3.7) it became clear that βTrCP knockdown with 400nM 
siRNA resulted in a significant reduction in glucose uptake of about 40%.  These 
data along with the fact GLUT4 levels are not reduced under βTrCP knockdown 
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could indicate that GLUT4 is not being targeted to the insulin responsive 
compartment.  As βTrCP is an E3 ligase and we know that a mutant of GLUT4 
that cannot be ubiquitinated does not respond to insulin it is possible that 
reducing levels of βTrCP results in GLUT4 failing to be ubiquitinated and in turn 
it is not targeted to the insulin responsive compartment.   
To fully test this in future, ubiquitin pulldown of GLUT4 in βTrCP knockdown 
cells could be used to identify if GLUT4 is being ubiquitinated (Lamb et al. 
2010).  Another choice may be to look at another candidate E3 ligase such as 
Nedd4.  The Nedd4-like ubiquitin ligase Rsp5p has been shown to be responsible 
for ubiquitination of Gap1p in Saccharomyces cerevisiae (Shiga et al. 2014)and as 
Gap1p and GLUT4 have been shown to have a similar trafficking pathways 
(Shewan et al. 2013) it would be a sensible target to investigate.  Utilising 
similar knockdown experiments would help to identify if Nedd4 could play a role 
in ubiquitination of GLUT4. 
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4 Chapter 4 
4.1 Introduction 
Previous studies from our group have established that ubiquitination is required 
for entry of GLUT4 into GLUT4 storage vesicles (GSVs)(Lamb et al. 2010).  
Ubiquitination alone however does not maintain GLUT4 in GSVs as ubiquitination 
of membrane proteins normally leads to degradation at the lysosome (Hicke & 
Dunn 2003; Urbé 2005) and, expression of a constitutively ubiquitinated version 
of GLUT4 (HA-GLUT4 7K/R-Ub) fails to translocate to the plasma membrane in 
response to insulin, and remains in the syntaxin 16 positive perinuclear 
compartment (McCann R.K. PhD thesis ). Previous studies have also shown that 
only about 0.1% of GLUT4 is ubiquitinated (Lamb et al. 2010), and looking at 
these data together suggests that ubiquitination of GLUT4 is transient and 
therefore requires a deubiquitination step. 
Deubiquitinating enzymes (DUBs) function to maintain free ubiquitin levels and 
to promote stability of ubiquitinated substrates (Komander et al. 2009).  
Receptor recycling and resensitisation in the endosomal system has been shown 
to require DUBs; internalisation of the 2 adrenergic receptor requires 
ubiquitination of the receptor and subsequent deubiquitination by ubiquitin 
specific protease (USP) 20 and 33 (Berthouze et al. 2009).  Ubiquitination of the 
receptor triggers internalisation upon ligand binding and targets it toward the 
lysosome, deubiquitination of the receptor rescues it from degradation and 
returns it to the cells surface for subsequent stimulation and internalisation.  
Previous studies in our lab and from others suggest that USP25 may be the DUB 
acting to deubiquitinate GLUT4 and maintain GLUT4 stability in GSVs. 
The insulin responsive amino peptidase IRAP is one of the main cargo 
components of GSVs, and traffics in an identical manner to GLUT4 under both 
basal and insulin stimulated conditions (Ross et al. 1997b).  Depletion of IRAP 
utilising siRNA in 3T3-L1 adipocytes has been shown to reduce insulin stimulated 
translocation of GLUT4 however depletion of GLUT4 does not seem to have a 
similar effect on IRAP (Yeh et al. 2007). These data suggest IRAP is involved in 
maintaining GLUT4 in GSVs and provides a link to USP25.  IRAP has been shown 
to interact with the poly-ADP ribose polymerase (PARP) Tankyrase, via a minimal 
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tankyrase binding motif (RXX(P,A)DG) (Chi & Lodish 2000), and tankyrase has 
been shown to interact with the DUB USP25 through yeast two hybrid analysis 
(Sbodio & Chi 2002).   Further work carried out in our lab (Lamb, C thesis) used 
in vitro pulldown to show that tankyrase from 3T3-L1 adipocytes interacts with 
GST-USP25 but not with GST-USP25 R1049A which contains a mutation in the 
previously identified Tankyrase binding site (Chi & Lodish 2000). 
siRNA depletion of USP25 in 3T3-L1 adipocytes has been shown to result in lower 
expression levels of GLUT4 and to reduce insulin stimulated glucose uptake.  
Taken together these data suggest a model where IRAP and tankyrase form a 
scaffold on GSVs that allows USP25 to bind and deubiquitinate GLUT4.  This 
cycling of ubiquitination and deubiquitination would allow GLUT4 to enter and 
be retained in GSVs.  Reduction of USP25 expression through siRNA knockdown 
prevents deubiquination of GLUT4 and GLUT4 is transported to the lysosome and 
degraded. 
4.2 Aims of the chapter 
The overall aim of the work presented in this chapter was to further test the 
model outlined above.  To this end, I investigated whether GLUT4 and USP25 
colocalise in 3T3-L1 adipocytes.  I also set out to characterise the role of the 
deubiquitinating enzyme USP25 in GLUT4 sorting.  Specifically I wanted to ask 
whether USP25’s deubiquitinase activity is required to stabilise GLUT4 in GSVs.  I 
aimed to address this by expressing siRNA resistant USP25, and a catalytically-
inactive version thereof, in USP25 depleted cells, and comparing their abilities 
to rescue the observed reduced levels of GLUT4 and insulin-responsive glucose 
uptake. 
To pursue the above aims, I first embarked on a series of ‘tool building’ to 
gather the necessary reagents. 
4.3 Affinity purification of USP25 antisera 
Utilising the human USP25 sequence published in (Bosch-Comas et al. 2006), our 
group generated USP25 antisera that could detect USP25 in adipocyte lysate 
(Christopher Lamb PhD thesis).  In addition to recognising USP25, this antisera 
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also recognises a number of other proteins in adipocyte lysates.  To address this 
issue I set out to clean up the antibody for use in further experiments.  As the 
final bleed had been shown to detect USP25 to a greater degree than other 
available sera I chose this as my starting material.  Purification of antibodies was 
carried out as detailed in section 2.4.5 and the resulting material was used in 
immunoblot analysis of adipocyte lysates (Figure 4.1).  To characterise the 
purified antibody, I used it at a 1:1000 dilution in immunoblot analysis of lysates 
prepared from 3T3-L1 adipocytes.  The left hand panel of Figure 4.1 shows that 
the purified antibody recognises several bands in the adipocyte lysates (although 
not as many as seen with the unpurified sera; Christopher Lamb, PhD thesis).  To 
investigate which, if any, of these are specific to USP25, I ran a second 
immunoblot analysis in parallel, with the same lysates but this time probed with 
1:1000 of the purified antibody in the presence of 4μg/ml of GST-USP25 (right 
hand panel of Figure 4.1). 
 
Figure 4.1 Characterisation of anti-USP25 antibodies 
Lysates (20μg protein) prepared from 3 independent passages of 3T3-L1 adipocytes were subject 
to immunoblot analysis following separation on a 7.5% (v/v) SDS-PAGE gel.  The two panels 
shown represent identical blots with the left hand panel being probed with purified USP25 antibody 
and the right hand panel being probed with the same in the presence of 4μg/ml recombinant GST-
USP25.  
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A band of approximately 140kD (the observed molecular weight of USP25; 
(Meulmeester et al. 2008) can be seen in all lanes of the left hand panel 
(indicated by the red arrow), but is missing from the right hand panel.  Given 
that the only difference between this is the inclusion of GST-USP25 in the 
primary antibody step, this band is likely to represent USP25. 
4.4  Identification of suitable siRNA for USP25 
knockdown 
With a suitable antibody available to detect USP25 for western blotting I then 
needed to identify a suitable method for depletion of endogenous USP25 for use 
in further experiments.  A well established method of depleting proteins of 
interest without having to knock out the gene of interest is RNA interference 
(RNAi) (Elbashir et al. 2001).  To this end I used the Mirus TransIT-TKO® 
transfections system (detailed 2.2.3) and two oligonculeotides (siRNA25 and 
siRNA27 detailed table 2.2) already available to our lab.  3T3-L1 adipocytes were 
transfected with 50nM siRNA on days 6 and 7 post differentiation and harvested 
on day 8.  Lysates were run on SDS-PAGE prior to immunoblot analysis utilising 
the previously characterised USP25 antibody.  The immunoblots were quantified 
utilising ImageJ software by normalising intensities of USP25 against a band of 
unknown origin at 75kDa the results are shown in figure 4.2. 
These data indicate that USP25 is depleted by both siRNA25 and siRNA27 when 
compared to the scrambled siRNA control 54% ± 20% and 27% ± 2.5% respectively.  
These data indicates that siRNA27 provided a more robust and consistent 
knockdown of USP25 and I therefore decided it would be used in future 
experiments. 
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Figure 4.2 Immunoblot analysis of 3T3-L1 adipocytes treated with siRNA specific to USP25 
shows a reduction in USP25 levels 
(Left panel)3T3-L1 adipocytes were treated with 50nM of the indicated siRNA using Mirus TransIT 
TKO transfection reagent on days 6 and 7 post differentiation, harvested on day 8 and 
immunoblotted for USP25. (Right panel) Levels of USP 25 (band indicated by red arrow) were 
analysed using imageJ software and normalised against the band of unknown origin at 
approximately 75 kDa. 
 
4.5 Production of tuneable myc-USP25 and myc-USP25 
C178S 
Work carried out previously in our lab has shown that using a retro-viral  method 
to express USP25 in 3T3-L1 adipocytes prevents them from successfully 
differentiating.  To overcome this problem I employed an inducible virus system 
that would allow expression of USP25 constructs to be triggered post 
differentiation.  I chose to utilise the Proteo Tuner™ system which allows for 
titratable expression of the desired protein by controlling the concentration of 
the induction reagent Shield1.  The pRetroX tuner plasmid expresses a 
destabilisation domain attached to your protein of interest leading to rapid 
degradation under normal circumstances.  When Shield1 is added it binds to the 
destabilisation domain and prevents it from being recognised.  With the 
destabilisation domain blocked your protein of interest is then expressed, and 
this expression is titrable by altering the concentration of Shield1 used.  
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Polymerase chain reaction was used to produce a USP25 product encoding myc 
tagged human USP25 and was flanked by NotI and BAMHI restriction 
endonuclease sites. The resultant product was sub-cloned into the pCR2.1 vector 
containing NotI and BAMHI restrictions sites.    After sub-cloning into pCR2.1 site 
directed mutagenesis was used to produce a product encoding USP25 C178S a 
catalytically inactive mutant (Denuc et al. 2009). I used pCR2.1 as my vector for 
the SDM as it already contained the NotI and BAMHI restrictions sites I required 
for sub-cloning into the pRetroX-Tuner vector.  Utilising theses restriction sites 
the wild type USP25 and the USP25 C178S were ligated into the pRetroX Tuner 
vector to be used in viral production.  Both constructs were transfected into 
Plat-E packaging cells to produce recombinant retrovirus as described in 2.2.6. 
The platinum-E packaging cells express viral coat proteins not expressed in the 
pRetroX vector and as such produce a virus that can infect cells but cannot 
produce and infectious virus in the infected cell line.  Sub confluent 3T3-L1 
fibroblasts were infected with the resulting product, grown to confluency and 
differentiated into adipocytes.  Infected adipocytes were treated for 24 hours 
with varying concentrations of Shield1 and subsequent lysates were 
immunoblotted for myc-USP25 (figure4.3).  Initial experiments showed that only 
the USP25 C178S was expressed upon Shield1 induction. 
 
Figure 4.3 myc USP25 C178S expression increases as Shield1 concentration increases 
3T3-L1 fibroblasts were infected with retroviral constructs encoding Myc-USP25 C178S. Between 
days 8-12 post differentiation infected cells were treated for 24 hours with the Shield1 reagent in a 
concentration range from 0.25μM-1μM.  Infected adipocytes were subject to immunoblot analysis 
following separation on a 7.5% (v/v) SDS-PAGE 
As both sequences had been sequenced prior to viral production, and were 
shown to be correct, it was assumed that the initial viral batch of Wt USP25 had 
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failed to infect the 3T3-L1 adipocytes.  After multiple attempts to produce virus 
that would express wild type USP25 it was decided to use USP25 C178S as a 
template (as we knew it expressed under Shield1 induction) and use SDM to get 
back to wild type USP25.  This method appeared to be successful as Figure 4.4 
shows expression of wt USP25 under Shield1 induction.   
 
Figure 4.4 Wt USP25 expression increases as Shield1 concentration increases 
3T3-L1 fibroblasts were infected with retroviral constructs encoding Myc-USP25. Between days 8-
12 post differentiation infected cells were treated for 24 hours with the Shield1 reagent in a 
concentration range from 0.25μM-1μM.  Infected adipocytes were subject to immunoblot analysis 
following separation on a 7.5% (v/v) SDS-PAGE. 
4.6 Discussion 
The aim of this chapter was to further characterise the interaction between 
GLUT4 and USP25.  To address this I set out on a series of tool building exercise.  
To allow for detection of USP25 by western blotting I set out to purify a 
previously available antibody.  As figure 4.1 shows a distinct band representing 
USP25 can be detected from 3T3-L1 adipocyte lysate.  With that success I then 
wanted to look at ways to express USP25 constructs in 3T3-L1 cells without 
inhibiting differentiation.  Utilising an inducible virus system I was able to 
express USP25 and USP25 C178S post differentiation (figure 4.3 and 4.4).  This 
system however proved unreliable as repeats even using virus produced from the 
same batch were unable to produce consistent results.  This method does show 
that USP25 can be expressed post differentiation in 3T3-L1 adipocytes and if this 
work was continued with a more robust system it could be used to further 
characterise the interaction between GLUT4 and USP25. 
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To address this infectivity problem in the future a lentiviral system could be 
used instead of the current retroviral system.  Lentivirus has previously been 
shown to be successful at infecting adipocytes and pre-adipocytes (Carlotti et al. 
2004) furthermore a proteo tuner inducible system of expression is available as a 
lentiviral vector.  Use of an inducible lentivrial system should allow expression of 
USP25 constructs reliably without inhibiting differentiation.  With this system in 
place it would be possible to identify if the catalytic activity of USP25 is 
required for GLUT4 to be maintained stably in GSVs. 
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